Stocks and Investing Stocks and Investing
Thu, September 29, 2022
Wed, September 28, 2022

Mohit Bansal Maintained (BIIB) at Buy with Increased Target to $350 on, Sep 28th, 2022


Published on 2024-10-27 23:07:59 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $265 to $350 on, Sep 28th, 2022.

Mohit has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Decreased Target to $223 on, Monday, September 12th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, July 21st, 2022


These are the ratings of the 4 analyists that currently disagree with Mohit


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $265 on, Thursday, September 22nd, 2022
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022
Contributing Sources